JP6759100B2 - 治療用阻害化合物 - Google Patents

治療用阻害化合物 Download PDF

Info

Publication number
JP6759100B2
JP6759100B2 JP2016544593A JP2016544593A JP6759100B2 JP 6759100 B2 JP6759100 B2 JP 6759100B2 JP 2016544593 A JP2016544593 A JP 2016544593A JP 2016544593 A JP2016544593 A JP 2016544593A JP 6759100 B2 JP6759100 B2 JP 6759100B2
Authority
JP
Japan
Prior art keywords
methyl
isonicotinamide
chloro
amino
fluoro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2016544593A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017501205A5 (enExample
JP2017501205A (ja
Inventor
マクドナルド，アンドリュー
Original Assignee
ライフサイ ファーマシューティカルズ，インク．
ライフサイ ファーマシューティカルズ，インク．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ライフサイ ファーマシューティカルズ，インク．, ライフサイ ファーマシューティカルズ，インク． filed Critical ライフサイ ファーマシューティカルズ，インク．
Publication of JP2017501205A publication Critical patent/JP2017501205A/ja
Publication of JP2017501205A5 publication Critical patent/JP2017501205A5/ja
Application granted granted Critical
Publication of JP6759100B2 publication Critical patent/JP6759100B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2016544593A 2013-12-30 2014-12-30 治療用阻害化合物 Expired - Fee Related JP6759100B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361921995P 2013-12-30 2013-12-30
US61/921,995 2013-12-30
US201462025203P 2014-07-16 2014-07-16
US62/025,203 2014-07-16
PCT/US2014/072851 WO2015103317A1 (en) 2013-12-30 2014-12-30 Therapeutic inhibitory compounds

Publications (3)

Publication Number Publication Date
JP2017501205A JP2017501205A (ja) 2017-01-12
JP2017501205A5 JP2017501205A5 (enExample) 2018-02-08
JP6759100B2 true JP6759100B2 (ja) 2020-09-23

Family

ID=53493998

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016544593A Expired - Fee Related JP6759100B2 (ja) 2013-12-30 2014-12-30 治療用阻害化合物

Country Status (11)

Country Link
US (2) US10266515B2 (enExample)
EP (1) EP3089746A4 (enExample)
JP (1) JP6759100B2 (enExample)
KR (1) KR20160106627A (enExample)
CN (1) CN106061480B (enExample)
AU (2) AU2014373735B2 (enExample)
BR (1) BR112016015449A8 (enExample)
CA (1) CA2935683A1 (enExample)
EA (1) EA032713B1 (enExample)
MX (1) MX2016008688A (enExample)
WO (1) WO2015103317A1 (enExample)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8563573B2 (en) 2007-11-02 2013-10-22 Vertex Pharmaceuticals Incorporated Azaindole derivatives as CFTR modulators
US8802868B2 (en) 2010-03-25 2014-08-12 Vertex Pharmaceuticals Incorporated Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
MX342288B (es) 2010-04-22 2016-09-23 Vertex Pharma Proceso para producir compuestos de cicloalquilcarboxamido-indol.
TWI636047B (zh) 2013-08-14 2018-09-21 英商卡爾維斯塔製藥有限公司 雜環衍生物
HUE14755117T2 (hu) 2013-08-14 2018-12-28 Kalvista Pharmaceuticals Ltd Plazma-kallikrein inhibitorok
US9611252B2 (en) 2013-12-30 2017-04-04 Lifesci Pharmaceuticals, Inc. Therapeutic inhibitory compounds
KR20160106627A (ko) 2013-12-30 2016-09-12 라이프에스씨아이 파마슈티컬스, 인크. 치료적 억제 화합물
KR102447581B1 (ko) 2014-04-15 2022-09-28 버텍스 파마슈티칼스 인코포레이티드 낭포성 섬유증 막전도 조절자 매개 질환 치료용 약제학적 조성물
EA035410B1 (ru) * 2014-07-16 2020-06-09 Лайфсай Фармасьютикалс, Инк. Терапевтические соединения-ингибиторы
GB201421085D0 (en) 2014-11-27 2015-01-14 Kalvista Pharmaceuticals Ltd New enzyme inhibitors
GB201421083D0 (en) 2014-11-27 2015-01-14 Kalvista Pharmaceuticals Ltd Enzyme inhibitors
US12282014B2 (en) 2015-11-19 2025-04-22 Dana-Farber Cancer Institute, Inc. Methods of identifying compounds that interfere with ERG-driven misguidance of BAF complexes in TMPRSS2-ERG driven prostate cancers
EP3404021A4 (en) 2016-01-12 2019-09-11 Nippon Chemiphar Co., Ltd. VOLTAGE-RELATED T-TYPE CALCIUM CHANNEL INHIBITOR
SG10201913616UA (en) 2016-05-31 2020-03-30 Kalvista Pharmaceuticals Ltd Pyrazole derivatives as plasma kallikrein inhibitors
GB201609603D0 (en) 2016-06-01 2016-07-13 Kalvista Pharmaceuticals Ltd Polymorphs of N-[(6-cyano-2-fluoro-3-methoxyphenyl)Methyl]-3-(methoxymethyl)-1-({4-[(2-ox opyridin-1-YL)Methyl]phenyl}methyl)pyrazole-4-carboxamide
GB201609607D0 (en) 2016-06-01 2016-07-13 Kalvista Pharmaceuticals Ltd Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts
EP3481391A4 (en) 2016-07-11 2020-03-11 Lifesci Pharmaceuticals, Inc. Therapeutic inhibitory compounds
CN107033015B (zh) * 2017-06-02 2019-04-30 南京欧信医药技术有限公司 一种药物中间体的合成方法
GB201719881D0 (en) 2017-11-29 2018-01-10 Kalvista Pharmaceuticals Ltd Solid forms of plasma kallikrein inhibitor and salts thereof
MX2020005168A (es) 2017-11-29 2020-08-20 Kalvista Pharmaceuticals Ltd Formas de dosificacion que contienen un inhibidor calicreina de plasma.
EP3746124A4 (en) 2018-01-30 2021-10-27 Foghorn Therapeutics Inc. COMPOUNDS AND THEIR USES
WO2019166874A1 (en) * 2018-02-28 2019-09-06 Lifesci Pharmaceuticals, Inc. Treatment of hereditary angioedema
IL277071B2 (en) 2018-03-08 2024-07-01 Incyte Corp AMINOPYRAZINE DIOL COMPOUNDS AS PI3K-y INHIBITORS
WO2019178129A1 (en) 2018-03-13 2019-09-19 Shire Human Genetic Therapies, Inc. Substituted imidazopyridines as inhibitors of plasma kallikrein and uses thereof
KR20210016545A (ko) 2018-05-29 2021-02-16 오메로스 코포레이션 Masp-2 억제제 및 사용 방법
US11584714B2 (en) 2018-05-29 2023-02-21 Omeros Corporation MASP-2 inhibitors and methods of use
US11046658B2 (en) 2018-07-02 2021-06-29 Incyte Corporation Aminopyrazine derivatives as PI3K-γ inhibitors
WO2020081588A1 (en) 2018-10-17 2020-04-23 Dana-Farber Cancer Institute, Inc. Swi/snf family chromatin remodeling complexes and uses thereof
US12384776B2 (en) 2019-01-29 2025-08-12 Foghorn Therapeutics Inc. Compounds and uses thereof
CN110256342B (zh) * 2019-07-16 2022-06-07 河南省科学院化学研究所有限公司 一种2-氰基喹啉衍生物的合成方法
WO2021028645A1 (en) 2019-08-09 2021-02-18 Kalvista Pharmaceuticals Limited Plasma kallikrein inhibitors
PT4031547T (pt) 2019-09-18 2024-08-27 Takeda Pharmaceuticals Co Inibidores de calicreína plasmática e utilizações dos mesmos
WO2021055589A1 (en) 2019-09-18 2021-03-25 Shire Human Genetic Therapies, Inc. Heteroaryl plasma kallikrein inhibitors
CN115103709A (zh) 2019-12-04 2022-09-23 奥默罗斯公司 Masp-2抑制剂和使用方法
IL293588A (en) 2019-12-04 2022-08-01 Omeros Corp 2-masp inhibitor compounds, preparations containing them and their uses
AU2020395306B2 (en) 2019-12-04 2025-04-24 Omeros Corporation MASP-2 inhibitors and methods of use
CR20220316A (es) 2019-12-06 2022-10-07 Vertex Pharma Tetrahidrofuranos sustituidos como moduladores de canales de sodio
JP7561195B2 (ja) 2020-01-29 2024-10-03 フォグホーン セラピューティクス インコーポレイテッド 化合物及びその使用
EP4096668A4 (en) * 2020-01-29 2024-02-28 Foghorn Therapeutics Inc. Compounds and uses thereof
US12383555B2 (en) 2020-05-20 2025-08-12 Foghorn Therapeutics Inc. Methods of treating cancers
JP2024522292A (ja) 2021-06-04 2024-06-13 バーテックス ファーマシューティカルズ インコーポレイテッド ナトリウムチャネルのモジュレーターとしてのｎ－（ヒドロキシアルキル（ヘテロ）アリール）テトラヒドロフランカルボキサミド
TW202337455A (zh) 2021-12-09 2023-10-01 美商迪賽孚爾製藥有限公司 Ｒａｆ激酶抑制劑及其使用方法
WO2024059186A1 (en) * 2022-09-15 2024-03-21 Takeda Pharmaceutical Company Limited N-((isoquinolin-6-yl)methyl)-1h-pyrazole-4-carboxamid derivatives as plasma kallikrein inhibitors for the treatment of hereditary angioedema
CN119604497A (zh) * 2023-06-30 2025-03-11 远森制药（杭州）有限公司 杂芳族甲酰胺类化合物及其在医药上的应用
WO2025160190A1 (en) * 2024-01-23 2025-07-31 Retune Pharma Inc. Therapeutic inhibitory compounds

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW212792B (enExample) * 1991-09-13 1993-09-11 Shell Internat Res Schappej B V
IL108459A0 (en) * 1993-02-05 1994-04-12 Opjohn Company 4-Hydroxy-benzopyran-2-ones and 4-hydroxy-cycloalkyl [B] pyran-2-ones useful for treating infections due to hiv and other retroviruses
AU707748B2 (en) 1994-03-25 1999-07-22 Isotechnika Inc. Enhancement of the efficacy of drugs by deuteration
US6334997B1 (en) 1994-03-25 2002-01-01 Isotechnika, Inc. Method of using deuterated calcium channel blockers
TW575562B (en) * 1998-02-19 2004-02-11 Agrevo Uk Ltd Fungicides
DK1228067T3 (da) * 1999-11-10 2004-12-06 Takeda Chemical Industries Ltd 5-leddede heterocykliske forbindelser med hypoglykæmisk og hypolipidæmisk virkning
EA007987B1 (ru) * 2002-03-29 2007-02-27 Чирон Корпорейшн Замещённые бензазолы и их применение в качестве ингибиторов киназы raf
EP1603884A4 (en) * 2003-02-28 2008-05-28 Encysive Pharmaceuticals Inc PYRIDINE, PYRIMIDINE, QUINOLINE, QUINAZOLINE AND NAPHTHALENE UROTENSIN II RECEPTOR ANTAGONISTS
GB0403155D0 (en) * 2004-02-12 2004-03-17 Vernalis Res Ltd Chemical compounds
KR20070066988A (ko) * 2005-12-22 2007-06-27 크리스탈지노믹스(주) 단백질 키나아제 활성을 저해하는 아미노 피리미딘유도체와 이의 제조방법 및 이를 유효성분으로 함유하는약학 조성물
US20070254894A1 (en) * 2006-01-10 2007-11-01 Kane John L Jr Novel small molecules with selective cytotoxicity against human microvascular endothelial cell proliferation
JP2009528992A (ja) 2006-02-16 2009-08-13 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 可溶性エポキシド加水分解酵素阻害剤として有益な置換ピリジンアミン化合物
CL2007003609A1 (es) * 2006-12-14 2008-07-25 Bayer Schering Pharma Ag Compuestos derivados de dihidropiridinas sustituidas; proceso de preparacion; compuestos intermediarios; composicion farmaceutica; proceso para producir la composicion farmaceutica; y uso en el tratamiento de una enfermedad mejorada con la inhibicion
EP2129670A2 (en) * 2007-02-16 2009-12-09 Glaxo Group Limited Benzofuran compounds useful in the treatment of conditions mediated by the action of pge2 at the ep1 receptor
EP2002834A1 (de) * 2007-06-13 2008-12-17 Bayer Schering Pharma Aktiengesellschaft Aryl/Hetarylamide als Modulatoren des EP2-Rezeptors
WO2009083553A1 (en) * 2007-12-31 2009-07-09 Rheoscience A/S Azine compounds as glucokinase activators
EP2269990A4 (en) * 2008-03-25 2012-04-18 Takeda Pharmaceutical Heterocyclic compound
US20090270407A1 (en) 2008-04-25 2009-10-29 E. I. Du Pont De Nemours And Company Fungicidal isoxazolidines
CN102099339A (zh) 2008-07-18 2011-06-15 武田药品工业株式会社 苯并氮杂衍生物及其作为组胺h3拮抗剂的用途
US8598209B2 (en) 2008-10-31 2013-12-03 Merck Sharp & Dohme Corp. P2X3, receptor antagonists for treatment of pain
WO2010108733A1 (en) * 2009-03-26 2010-09-30 Syngenta Participations Ag Insecticidal compounds
GB201004739D0 (en) * 2010-03-22 2010-05-05 Prosidion Ltd Receptor modulators
US9290485B2 (en) * 2010-08-04 2016-03-22 Novartis Ag N-((6-amino-pyridin-3-yl)methyl)-heteroaryl-carboxamides
MX366318B (es) * 2010-11-19 2019-07-05 Ligand Pharm Inc Derivados de aminas heterocíclicas que inhiben la transducción de señal mediana por cinasa asociada con el receptor de interleucina-1.
GB201021103D0 (en) * 2010-12-13 2011-01-26 Univ Leuven Kath New compounds for the treatment of neurodegenerative diseases
US9321727B2 (en) * 2011-06-10 2016-04-26 Hoffmann-La Roche Inc. Pyridine derivatives as agonists of the CB2 receptor
CN102904742B (zh) 2011-07-29 2015-10-07 华为终端有限公司 对可执行节点的操作方法及系统
WO2013040436A2 (en) 2011-09-16 2013-03-21 The Regents Of The University Of Michgian Esx-mediated transcription modulators and related methods
US9206128B2 (en) * 2011-11-18 2015-12-08 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
EP2807157A1 (en) * 2012-01-27 2014-12-03 Novartis AG 5-membered heteroarylcarboxamide derivatives as plasma kallikrein inhibitors
EP2807156A1 (en) 2012-01-27 2014-12-03 Novartis AG Aminopyridine derivatives as plasma kallikrein inhibitors
EA027780B1 (ru) 2012-12-07 2017-08-31 Ф.Хоффманн-Ля Рош Аг Пиридин-2-амиды, пригодные в качестве агонистов каннабиноидного рецептора 2
RU2712621C2 (ru) 2013-05-23 2020-01-30 Калвиста Фармасьютикалз Лимитед Азотсодержащие гетероциклические производные, полезные в качестве ингибитора калликреина плазмы
HUE14755117T2 (hu) 2013-08-14 2018-12-28 Kalvista Pharmaceuticals Ltd Plazma-kallikrein inhibitorok
US9611252B2 (en) 2013-12-30 2017-04-04 Lifesci Pharmaceuticals, Inc. Therapeutic inhibitory compounds
KR20160106627A (ko) 2013-12-30 2016-09-12 라이프에스씨아이 파마슈티컬스, 인크. 치료적 억제 화합물
EA035410B1 (ru) 2014-07-16 2020-06-09 Лайфсай Фармасьютикалс, Инк. Терапевтические соединения-ингибиторы
GB201421088D0 (en) 2014-11-27 2015-01-14 Kalvista Pharmaceuticals Ltd New enzyme inhibitors
EP3481391A4 (en) 2016-07-11 2020-03-11 Lifesci Pharmaceuticals, Inc. Therapeutic inhibitory compounds

Also Published As

Publication number Publication date
EP3089746A4 (en) 2017-08-30
US20180170906A1 (en) 2018-06-21
MX2016008688A (es) 2017-01-12
KR20160106627A (ko) 2016-09-12
US20200031799A1 (en) 2020-01-30
AU2020201550A1 (en) 2020-03-19
BR112016015449A8 (pt) 2020-06-09
EA032713B1 (ru) 2019-07-31
CA2935683A1 (en) 2015-07-09
CN106061480A (zh) 2016-10-26
CN106061480B (zh) 2020-02-28
JP2017501205A (ja) 2017-01-12
US10266515B2 (en) 2019-04-23
AU2014373735B2 (en) 2020-03-12
WO2015103317A1 (en) 2015-07-09
EA201691354A1 (ru) 2016-12-30
AU2014373735A1 (en) 2016-08-11
EP3089746A1 (en) 2016-11-09

Similar Documents

Publication Publication Date Title
JP6759100B2 (ja) 治療用阻害化合物
EP3033336B1 (en) Inhibitors of plasma kallikrein
US10730863B2 (en) Bridged bicyclic compounds as farnesoid X receptor modulators
CN104428293B (zh) 调节TNFα的苯并咪唑类
KR100908176B1 (ko) 인자 Ｘａ 억제제로서의 락탐-함유 화합물 및 그의 유도체
US9181272B2 (en) Aldosterone synthase inhibitors
WO2005063738A1 (ja) 新規２－へテロアリール置換ベンズイミダゾール誘導体
WO2016011390A1 (en) Irak4 inhibiting agents
JP2009517383A (ja) 新規な３−ビシクロカルボニルアミノピリジン−２−カルボキサミド又は３−ビシクロカルボニルアミノピラジン−２−カルボキサミド
JP5036316B2 (ja) アリールオキシ置換ベンズイミダゾール誘導体
KR20090125779A (ko) 브라디키닌 ｂ2 수용체 조절제로서 8-옥시-퀴놀린 유도체
JP2014001228A (ja) Ｈ−ｐｇｄｓの阻害剤としてのマルチヘテロアリール化合物及びプロスタグランジンｄ２を介した疾患を治療するための該化合物の使用
TW202339734A (zh) 用於抑制ｙａｐ／ｔａｚ－ｔｅａｄ之２－吡唑苯胺及相關類似物
CN114650993B (zh) 一种pd-1/pd-l1抑制剂及其制备方法和用途
JP2024542145A (ja) Ｐｒｍｔ５阻害剤としての２－アミノイミダゾール誘導体
WO2022167819A1 (en) Novel compounds
TW202337457A (zh) 新穎苯并咪唑吡啶衍生物
US20220153724A1 (en) Inhibitors Of Plasma Kallikrein
WO2025059562A1 (en) Substituted aminopyridine compounds and methods of treating disease using same
HK1230502B (zh) 治疗性抑制性化合物
HK1230502A1 (en) Therapeutic inhibitory compounds

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160819

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171223

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20171223

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20180830

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180910

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20181206

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190201

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190228

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190318

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190604

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190917

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A132

Effective date: 20191002

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20191220

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200401

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200805

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20200902

R150 Certificate of patent or registration of utility model

Ref document number: 6759100

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees